The platinum (II) 
INTRODUCTION
Cisplatin, cis-[PtCl2(NHs)2], is a widely used antieaneer drug. The drug's greatest therapeutical impact was found to be on testieular and ovarian cancers/1/. It has also proved to be of benefit in the treatment of wide variety of other solid tumors (head and neck, lung, bladder, eoloreetal and breast cancer) in combination chemotherapy regimens. Because of its severe toxicity profile and the spontaneous development of drug resistance in tumors, numerous Pt(II) and Pt(IV) complexes have been synthesized and tested for antitumor activity/3/. The principal goal of these investigations is obtaining an antitumor drug with higher solubility, better antitumor activity, and lower toxicity. However, at present, only several platinum(II) complexes (earboplatin and oxaliplatin) have shown substantial antieaneer activity in clinical settings. Despite this progress, the search for other platinum chemotherapeutic agents is continuing, since the carboplatin and other second-generation platinum(ll) complexes, although less toxic than cisplatin, appear to be highly crossresistant with cisplatin.
The great majority of the second-generation antitumor active platinum complexes are structural analogues of cisplatin with two ammine or amine groups in cis-position. The Combinations of platinum(II) complexes and taxol were analyzed by median effect method, primarily under the assumption that drug mechanisms of action were mutually, nonexclusive i.e. were completely independent. A drug combination index (CI) was calculated for three different levels of cytotoxicity (25; 50 and 75%). On simultaneous exposure of cells to taxol and platinum(II) complexes no consistent effect was found. The CIs for drug combinations revealed cytotoxic effects that were in most cases synergistic (Pt l) and less than additive (Pt2). Median effect analysis showed that interaction of platinum(If) complexes and taxol varies, depending not only on the type of complex, but also on the cytotoxicity level (Figures 4 and 5) .
It is well known that cisplatin can induce apoptosis in various cells, in any cell cycle phase, as a function of drug concentration and exposure duration, but a period of cell cycle "stasis" precedes the onset of apoptosis [5, 13, The tested platinum(ll) complexes are cisplatin analogues. It is recognized that manipulation of the structure of the leaving groups appears to influence tissue and intracellular distribution of the complexes, but upon interacting with DNA, the stable, carrier groups presumably determine the structure of the adduct. The ultimate aim of the modifications of the parent drug is to make analogues that produce a different spectrum of DNA lesions and so circumvent the problem of resistance to cisplatin/1/. It seems that differences related to carrier ligands influence both types and frequencies of DNA lesions formed, and consequently, various growths inhibiting activity could be expected.
Cis-configuration of the tested platinum(ll) complexes was identified as potentially critical for antineoplastic activity. They are platinum(ll) structures assuming planar shape. Both of them have chlorine atoms for so-called leaving groups. The 
CONCLUSION
This study showed that two Ptl and Pt2 complexes containing thio ligands influence the MCF7 cells growth more effectively as compared to the parent drug. However, they differ in their cytotoxicity profiles and in their interaction with taxol as well. The cell cycle changes and induction of apoptosis in MCF7 cells implicate a programmed cell death pathway in cell-killing.
